MaaT Pharma SA (EPA: MAAT)

Market Cap	115.46M
Revenue (ttm)	2.57M
Net Income (ttm)	-24.14M
Shares Out	13.98M
EPS (ttm)	-2.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,102
Average Volume	9,551
Open	8.10
Previous Close	8.00
Day's Range	8.04 - 8.30
52-Week Range	6.52 - 9.96
Beta	0.18
RSI	53.83
Earnings Date	Mar 26, 2025

About MaaT Pharma

MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival in patients with acute myeloid leukemia or blood cancer receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 60
• Stock Exchange: Euronext Paris
• Ticker Symbol: MAAT

Financial Performance

In 2023, MaaT Pharma's revenue was 2.23 million, an increase of 55.80% compared to the previous year's 1.43 million. Losses were -19.72 million, 43.8% more than in 2022.